Celera and Merck link up on Alzheimer's:
This article was originally published in Clinica
Executive Summary
Celera Diagnostics has joined forces with Merck & Co to identify novel targets for drug discovery and diagnostic markers related to Alzheimer's disease. Alameda, California-based Celera will conduct a functional genome scan to pinpoint novel gene variations associated with the disease, and will retain rights for diagnostic applications from the studies. Merck will receive rights for therapeutic applications from the studies in Alzheimer's disease, as well as for certain other neurological disorders. It will also fund discovery research at Celera related to the collaboration, and will make certain clinical milestone payments and pay a royalty on sales of pharmaceutical products it commercialises as a result of the study.